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One year ago, in this journal, we published a recommended
nomenclature for the neuropathologic subtypes of fronto-
temporal lobar degeneration (FTLD) [7]. A major impetus
behind this was to resolve the confusion that had arisen
around the use of the term ‘‘FTLD with ubiquitinated
inclusions’’ (FTLD-U), following the discovery that the
molecular pathology of these cases was heterogeneous,
with most, but not all, being characterized by pathological
TDP-43 [6, 11]. In addition, a system of nosology was
introduced that grouped the FTLD subtypes into broad
categories, based on the molecular defect that is most
characteristic, according to current evidence. This system
provided a concise and consistent terminology that has now
been widely adopted in the literature. Another anticipated
advantage was the ability to readily accommodate new
discoveries. At the time, we did not anticipate how quickly
this attribute would be put to use.
Although most FTLDs are characterized by cellular
inclusion bodies composed of either tau (FTLD-tau) or
TDP-43 (FTLD-TDP), approximately 10–15% of cases
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remain, that include a number of uncommon FTLD sub-
types, in which the pathologic protein is unknown.
Recently, two studies identified mutations in the gene
encoding the fused in sarcoma (FUS) protein (also known
as translocated in liposarcoma, TLS), as the cause of
familial amyotrophic lateral sclerosis (ALS) type 6 [5, 14].
The recognized clinical, genetic and pathological overlap
between ALS and FTD, and the high degree of functional
homology between FUS and TDP-43, prompted a number
of subsequent studies that demonstrated that the inclusions
of several of the tau/TDP-43-negative FTLDs are immu-
noreactive (ir) for FUS [8–10]. One such group are those
cases with TDP-43-negative FTLD-U pathology, originally
referred to as atypical FTLD-U (aFTLD-U) [6, 11].
According to the previous nomenclature recommendations,
the neuropathology of these cases was designated as
FTLD-UPS because the inclusions were only detectable
with immunohistochemistry against proteins of the ubiq-
uitin proteasome system (UPS) [7]. However, based on the
discovery that all the ubiquitin-positive pathology in these
cases is immunoreactive for FUS, we now recommend that
they should be reclassified as FTLD-FUS [9]. In addition,
the characteristic neuronal cytoplasmic inclusions of
basophilic inclusions body disease (BIBD), previously of
unknown biochemical composition, have also been shown
to be consistently FUS-ir [8]. Perhaps most surprising has
been the identification of abundant FUS-positive pathology
in cases of neuronal intermediate filament inclusion disease
(NIFID) [10]. The diagnostic criterion for NIFID is the
presence of neuronal inclusions that are negative for tau,
a-synuclein and TDP-43 but immunoreactive for class IV
intermediate filaments (IF) [1] and therefore the term
FTLD-IF was designated in the previous nomenclature
recommendations [7]. However, the finding that only a
minority of the inclusions in NIFID are IF-ir, the absence
of any identifiable genetic or molecular abnormality of IF
in these cases and the recognition that immunohistochem-
istry for IF is not specific for this condition, is consistent
with the possibility that another protein may be more
central to the pathogenesis. The recent demonstration that a
much larger proportion of the inclusions in NIFID are FUS-
ir, that all the cells with IF-ir inclusions also contain
pathological FUS, and that there are widespread FUS-ir
glial inclusions, suggests that the abnormal accumulation
of FUS may be more fundamental in the disease process
and that IF pathology probably develops as a secondary
process [10].
Taking these studies together, we now recommend that
aFTLD-U, BIBD and NIFID should be grouped together
under the designation of FTLD-FUS (Table 1). It is
important to recognize, however, that this does not imply
that a defect in FUS metabolism is known to be causal in
any of these conditions. Rather, it simply indicates that
they share FUS accumulation as the most prominent
molecular pathology. Whether or not this indicates that
aFTLD-U, BIBD and NIFID are actually all part of a
continuous spectrum of disease must await detailed com-
parative clinicopathological studies of larger numbers of
cases. Nonetheless, the presence of FUS pathology sets
these cases apart and should aid in their neuropathological
diagnosis and classification.
Although it now appears that most, if not all, cases of
sporadic FTLD-UPS (i.e. aFTLD-U) have FUS-immu-
noreactive pathology [9], the designation FTLD-UPS
remains appropriate for at least one condition: familial
FTD linked to chromosome 3 (FTD-3), caused by
mutations in the CHMP2B gene. In addition to being
negative for tau and TDP-43 [2], a recent study has
shown that the ubiquitin/p62-immunoreactive neuronal
inclusions in these cases do not label with antibodies
against FUS [3]. Although these inclusions may even-
tually be discovered to contain a single major pathologic
protein, it is also possible they have more heterogeneous
composition that results from a primary defect of endo-
somal function [13]. Until this is determined, FTLD-UPS
remains an appropriate designation for the neuropathol-
ogy of FTD-3 and possibly for some FUS-negative
sporadic cases.
With these recent advances, virtually all cases of FTLD
can now be assigned to one of the three major molecular
subgroups (FTLD-tau, FTLD-TDP or FTLD-FUS). This
classification does not presuppose a primary role of the
signature protein in pathogenesis (although in FTLD-tau
and FTLD-TDP there is growing evidence to support this),
but provides a logical way of grouping neuropathologic
subtypes that is likely to have relevance regarding common
disease mechanisms, diagnostic tests and possibly treat-
ments. The specific role of the pathologic proteins and their
relationship to causal gene defects is crucial information
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that requires further neuropathological and experimental
investigations.
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Table 1 Updated nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration
2009 recommendation 2010 recommendation Associated genes
Major molecular class Recognized subtypesa Major molecular class Recognized subtypesa
FTLD-tau PiD
CBD
PSP
AGD
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NFT-dementia
WMT-GGI
Unclassifiable
FTLD-tau PiD
CBD
PSP
AGD
MSTD
NFT-dementia
WMT-GGI
Unclassifiable
MAPT
FTLD-TDP Types 1–4
Unclassifiable
FTLD-TDP Types 1–4
Unclassifiable
GRN
VCP
9p
(TARDBP)b
FTLD-UPS FTD-3
aFTLD-U
FTLD-UPS FTD-3 CHMP2B
FTLD-IF
BIBD
NIFID FTLD-FUS aFTLD-U
NIFID
BIBD
(FUS)c
FTLD-ni FTLD-ni
Entries in bold indicate major revisions
aFTLD-U, atypical frontotemporal lobar degeneration with ubiquitinated inclusions; AGD, argyrophilic grain disease; BIBD, basophilic
inclusion body disease; CBD, corticobasal degeneration; CHMP2B, charged multivescicular body protein 2B; FTD-3, frontotemporal dementia
linked to chromosome 3; FTLD, frontotemporal lobar degeneration; FUS, fused in sarcoma; GRN, progranulin gene; IF, intermediate filaments;
MAPT, microtubule associated protein tau; MSTD, multiple system tauopathy with dementia; NFT-dementia, neurofibrillary tangle predominant
dementia; ni, no inclusions; NIFID, neuronal intermediate filament inclusion disease; PiD, Pick’s disease; PSP, progressive supranuclear palsy;
TARDBP, transactive response DNA binding protein; TDP, TDP-43; UPS, ubiquitin proteasome system; VCP, valosin containing protein;
WMT-GGI, white matter tauopathy with globular glial inclusions; 9p, genetic locus on chromosome 9p linked to familial amyotrophic lateral
sclerosis and frontotemporal dementia
a Indicates the characteristic pattern of pathology, not the clinical syndrome. Note that FTDP-17 is not listed as a pathological subtype because
cases with different MAPT mutations do not have a consistent pattern of pathology. These cases would all be FTLD-tau, but further subtyping
would vary
b Rare case reports of patients with clinical FTD and TDP-43 pathology associated with TARDBP genetic variants [4]
c One patient reported with a FUS mutation and FTD/ALS clinical phenotype but no description of pathology [12]
Acta Neuropathol (2010) 119:1–4 3
123
8. Munoz DG, Neumann M, Kusaka H et al (2009) FUS pathology
in basophilic inclusion body disease. Acta Neuropathol 118:617–
627. doi:10.1007/s00401-009-0598-9
9. Neumann M, Rademakers R, Roeber S, Baker M, Kretzschmar
HA, Mackenzie IRA (2009) Frontotemporal lobar degeneration
with FUS pathology. Brain 132:2922–2931. doi:10.1093/brain/
awp214
10. Neumann M, Roeber S, Kretzschmar HA, Rademakers R, Baker
M, Mackenzie IRA (2009) Abundant FUS pathology in neuronal
intermediate filament inclusion disease. Acta Neuropathol
118:605–616. doi:10.1007/s00401-009-0581-5
11. Roeber S, Mackenzie IR, Kretzschmar HA, Neumann M (2008)
TDP-43-negative FTLD-U is a significant new clinico-
pathological subtype of FTLD. Acta Neuropathol 116:147–157.
doi:10.1007/s00401-008-0395-x
12. Ticozzi N, Silani V, LeClerc AL et al (2009) Analysis of FUS
gene mutation in familial amyotrophic lateral sclerosis within an
Italian cohort. Neurology 73:1180–1185. doi:10.1212/WNL.
0b013e3181bbff05
13. Urwin H, Ghazi-Noori S, Collinge J, Isaacs A (2009) The role of
CHMP2B in frontotemporal dementia. Biochem Soc Trans
37:208–212. doi:10.1042/BST0370208
14. Vance C, Rogelj B, Hortobagyi T et al (2009) Mutations in FUS,
an RNA processing protein, cause familial amyotrophic lateral
sclerosis type 6. Science 323:1208–1211. doi:10.1126/science.
1165942
4 Acta Neuropathol (2010) 119:1–4
123
